Related Experiment Video
Updated: Jul 16, 2026
10:13
Measuring G-protein-coupled Receptor Signaling via Radio-labeled GTP Binding
Published on: June 9, 2017
EFFECTS OF SOG ON DPP-RECEPTOR BINDING
Yuan Lou1, Qing Nie, Frederic Y M Wan
1Department of Mathematics, The Ohio State University, Columbus, OH 43210 ( lou@math.ohio-state.edu ).
SIAM Journal on Applied Mathematics
|March 23, 2007
Summary
The study reveals how Sog, a BMP ligand competitor, influences Dpp-receptor concentration gradients crucial for embryonic development. High Sog levels can create intense, transient Dpp activity near the dorsal midline, aligning with experimental findings.
Area of Science:
- Developmental Biology
- Biochemistry
- Mathematical Biology
Background:
- Morphogen gradients are essential for cell signaling and tissue patterning.
- BMP ligands play a critical role in embryonic development.
- Understanding how ligand-binding dynamics affect gradient formation is key.
Purpose of the Study:
- To analyze the effects of Sog, a BMP ligand competitor, on Dpp-receptor binding and gradient formation.
- To establish conditions for steady-state morphogen gradients in a prototype system.
- To investigate the impact of varying Sog production rates on Dpp activity.
Main Methods:
- Mathematical modeling of diffusing ligands, morphogen degradation, and complex cleavage.
- Establishing and proving existence theorems for steady-state gradient configurations.
- Numerical simulations to observe transient and steady-state dynamics.
Main Results:
- High Sog production rates lead to more intense Dpp-receptor concentration near the dorsal midline in steady states.
- Transient Dpp-receptor concentrations can exceed steady-state levels significantly beyond a threshold Sog production rate.
- The magnitude of transient Dpp activity increases with higher Sog production rates.
Conclusions:
- The presence of Sog can modulate BMP signaling intensity and spatial distribution.
- Transient Dpp activity spikes are a notable consequence of high Sog levels.
- These findings are consistent with experimental observations in embryonic development.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:12GPCR Desensitization
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:25Dose-Response Relationship: Selectivity and Specificity
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...